Philipp Mann
Wiesbaden, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Safety and immunogenicity of an mRNA COVID-19 vaccine administered to adults: A phase 2, randomized, active-controlled trial.
Journal: Human vaccines & immunotherapeutics
Published: August 26, 2026
Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation study.
Journal: Human vaccines & immunotherapeutics
Published: February 17, 2026
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
Journal: Human vaccines & immunotherapeutics
Published: October 18, 2024
Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity.
Journal: Vaccines
Published: February 13, 2024
Corrigendum to "Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study" [Vaccine: X 11 (2022) 100189].
Journal: Vaccine: X
Published: May 03, 2023
Validation of complex radiotherapy techniques using polymer gel dosimetry.
Journal: Physics in medicine and biology
Published: February 06, 2023
A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant.
Journal: Vaccines
Published: February 22, 2022
End-to-end test for fractionated online adaptive MR-guided radiotherapy using a deformable anthropomorphic pelvis phantom.
Journal: Physics in medicine and biology
Published: September 10, 2021
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Journal: The Lancet. Infectious diseases
Published: August 31, 2021
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.
Journal: Wiener klinische Wochenschrift
Published: July 02, 2021
Last Updated: 09/26/2026